Admission to AIM

Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR),
a specialty pharmaceutical company focused on respiratory disease, today announces that further to
the Company’s announcement on 10 December 2018 and the General Meeting on 4 January 2019, the
Board is pleased to confirm that the admission of the Company’s ordinary shares of 0.08 pence each
(the “Ordinary Shares”) to trading on AIM occurred at 8.00 a.m. today, 4 February 2019. The Ordinary
Shares have been removed from trading on the Main Market of London Stock Exchange plc and their
listing on the Official List has been cancelled.


Steve Harris, Chief Executive OfficerTel: +44 (0) 1865 405 560
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Dr. Christopher GoldenTel: +44 (0) 20 7418 8900
Numis Securities (Joint Broker)
James Black / Freddie BarnfieldTel: +44 (0) 20 7260 1000
FTI Consulting
Simon Conway / George KendrickTel: +44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia
sells its novel, market-leading NIOX® asthma management products directly to specialists in the
United States, United Kingdom, China and Germany, and in a wide range of other countries through
its network of partners. In 2017, the Company established a commercial collaboration with
AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease
(COPD) treatment Tudorza®. The Company has the commercial rights to NDA-stage COPD product
Duaklir®, and following the exercise of its option anticipates taking full commercial control of Tudorza®
in the US in 2019. Circassia also has the commercial rights to the late-stage ventilator-compatible
nitric oxide product AirNOvent in the United States and China. For more information please visit